Follow-up and outcomes
toxicities, SRS
RECURRENCES, DISEASE PROGRESSION, ADVERSE EVENT, BRAIN
Clinical and radiological evaluations have been performed at baseline, one month after treatment, and every 3 months after that, or until disease progression; they included history and physical examination, blood tests, and KPS. Hematologic and non-hematologic toxicities were graded according to Common Terminology Criteria for Adverse Events version 3.0. Brain MRI was performed aiming to differentiate post-treatment RN or disease progression. Methionine-CT/PET was performed in those cases with doubt images. An expert neuro-radiologist blindly assessed the response. Local recurrences were treated, and treatments could include surgery, SRS, or systemic agents if feasible. New distant BMs distinct from the treated sites were treated with SRS or WBRT in cases of leptomeningeal diffusion.